Venous thromboembolism (VTE) is the most common preventable cause of hospital-acquired mortality. VTE has an overall incidence of 110-130 per 100,000 with evidence that this is increasing. 1 Long-term complications of VTE, such as post-thrombotic syndrome or chronic thromboembolic pulmonary hypertension, are challenging to manage and are associated with a reduction in quality of life. Additionally, VTE is associated with an increase in healthcare costs of $18,000-23,000 per case, therefore representing a significant economic burden. 2 Prevention is a key component in the management of VTE and relies on the identification of patients who are most at-risk. Systematic use of risk assessment tools or models (RAMs) has been effective in reducing hospital-acquired VTE rates by enabling delivery of prophylaxis, and compliance to VTE RAM is now a metric to assess hospital performance. 3 Assessing which patients are at high-risk of VTE can be unclear at times. A validated objective marker of VTE risk is useful in aiding clinical judgement. Additionally, specific patient groups are particularly vulnerable to VTE, including oncological or trauma patients. However, is this the case for general medical and surgical patients, who represent the majority of inpatients?
In the United Kingdom, the National Institute for Health and Care Excellence (NICE) recommends the use of The Department of Health (DoH) Risk Assessment Tool for all hospital admissions. 4 Importantly, this is specific to the UK; different tools are used internationally. NICE conducted a review identifying 22 studies reporting on the validation of 13 RAMs. Evidence for the Caprini, International Medical Prevention Registry on Venous Thromboembolism (IMPROVE), Kucher, Padua, Intermountain, Khorana and Trauma Embolic Scoring System RAMs was deemed to be low, or very low, in quality. Furthermore, the RAMs were described as heterogeneous, 4 resulting in a lack of clarity regarding which RAM is the most accurate. This is an important consideration regarding a healthcare intervention that is ubiquitous and used as a metric to assess hospital performance.
So, what are the issues? Primarily, there is a concern regarding over-prescription of VTE prophylaxis -up to 42% of low-risk medical and surgical inpatients may be receiving prophylactic low-molecular weight heparin (LMWH) inappropriately. 5 Although prophylactic LMWH has a low side effect profile, a meta-analysis pooling data from 33,813 participants reported that LMWH was discontinued in 1.9% of patients. 6 Although major bleeding was rare (0.1-0.2%), the risk-benefit balance between VTE prevention and bleeding risk must be considered. This is of importance when considering the lack of grading in the DoH RAM and the potential for over-estimation of risk in ambulant elderly patients.
Over-prescription represents not only a potential risk to patients but also a significant cost to the national healthcare service (NHS). The NHS reported VTE risk assessments for 3.6 million adult inpatients across a three-month period, a significant allocation of resources. 7 Furthermore, in their report, NICE stated that using the IMPROVE instead of the DoH RAM would reduce expenditure by £22.3 million per year. 4 The DoH RAM has never been validated, nor have the two instruments ever been compared; therefore, there is currently no evidence to suggest that the DoH RAM is superior to the IMPROVE RAM. Cost-effectiveness is also a factor that should be taken into consideration; the current uncertainty on this topic has been highlighted by the recent National Institute for Health Research Health Technology Assessment call on the appraisal and cost effectiveness of current RAMs (HTA no. 18/19).
Thirdly, the inherent structure of existing RAMs and how they are graded is inconsistent. The DoH RAM functions as an 'aide-me´moire' based on a checklist of established clinical risk factors. Presence of a single element is indicative for thromboprophylaxis regardless of the 'weighing' of each component. This is important in clinical practice, as ambulant inpatients >60 years of age are graded equally to those whom have a known thrombophilia.
Conversely, most RAMs are based on cumulative risk scores, whilst the Padua and Caprini RAMs utilise a graded points-based system to provide overall risk stratification. However, these gradings can be weighted differently. For example, having a stroke within onemonth of admission scores 5 points in the Caprini RAM, whilst having an ischaemic stroke scores just 1 point in the Padua RAM. Additionally, Caprini requires measured homocysteine and anticardiolipin antibody values, resulting in increased time and cost. DoH, Padua and IMPROVE RAMs are based on clinical risk factors easily obtained from electronic record searches or patient histories. IMPROVE RAM consists of only seven graded clinical factors that can be completed online making it the shortest RAM providing a cumulative risk score of VTE alongside a bleeding risk.
Finally, validation of RAMs is varied. Padua RAM was developed in medical patients and validated in 63,548 inpatients with a Harrell's C score of 0.599 (0.594-0.606), 8 which raises concerns as to its discriminatory ability in identifying at-risk patients. IMPROVE RAM was also developed for medical inpatients and externally validated in a population of 19,217, reporting good discrimination between low (0-2) and high (3þ) risk scores (ROC ¼ 0.70). 9 Caprini RAM was developed in surgical patients using a retrospective analysis of 8216 inpatients, with an odds ratio of 1.9 between the Caprini riskstratification levels. 10 Interestingly, it has been validated in multiple surgical and medical populations. Despite this, limited sensitivity data have been reported and large prospective studies assessing all-specialty surgical patients are lacking.
Existing RAMs are heterogeneous, and there is no evidence to suggest which RAM is superior. VTE risk assessment represents a significant allocation of resources with little evidence to support the current strategy used within the NHS. Clinicians should ask themselves whether low-risk patients are being over-treated and if the evidence supporting VTE prophylaxis is representative of the population that the RAMs are being applied to.
Future studies should address hospital inpatients as a collective group and attempt to homogenise study design in order to make pooling of data possible. Current articles focus on specific patient groups and provide little evidence for blanket risk assessment of hospital inpatients. Ambiguity of current evidence means that there is no consensus on the method of VTE risk assessment that provides the best prediction of risk.
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